Cancer is a highly lethal disease with very urgent and unmet clinical needs. Tumor vaccines can be used to treat cancer, prevent cancer recurrence and metastasis. Currently, many domestic and international pharmaceutical companies are focusing on researching tumor neoantigen vaccines (in the form of peptides, mRNA, or DC),
There are issues with cancer neoantigens (peptides, mRNA, DC, etc.) vaccines:
(1) The preparation of vaccines is time-consuming (the shortest preparation cycle takes 2-4 months), labor-intensive, expensive, and has limited efficacy.
(2) Cancer cells and their antigens have high heterogeneity, and cancer cell mutations and antigens vary in different parts of the tumor. It is difficult to cover most cancer cells or their dominant antigens with 20-40 peptides or mRNA new antigens.
(3) The number of new antigens screened is limited and the accuracy is insufficient.
(4) Unable to screen and find hybrid peptides that account for one-third of the total antigen amount
(5) A high abundance of antigenic epitopes does not necessarily indicate strong immunogenicity.
The innovative breakthrough of Ersheng cancer vaccine: after tumor tissue is lysed, non water-soluble components are dissolved in a solubilized solution containing a solubilizer, which technically enables the co loading of cancer cell whole cell antigens and adjuvants into the same nanoparticle.
Vaccine characteristics:
(1) Take it from cancer, use it for cancer.
(2) The formulation has simple ingredients and a short preparation cycle (completed in 1-4 days).
(3) Nanoparticles are more easily engulfed by antigen-presenting cells (APCs) and are more efficient.
(4) By co loading antigens and adjuvants (intracellular targets) into the same nanoparticle and simultaneously being engulfed by the same APC, cancer antigen-specific T cells can be synergistically activated more efficiently, allowing them to only be activated as Teff and not Treg or incompetent T cells.
(5) The loaded antigens are diverse, broad-spectrum, and comprehensive; Stimulate broad-spectrum, diverse, and long-lasting cancer-specific immune responses.
(6) The cancer nanovaccine based on whole cell components is currently blank in the global market, and our patent is currently unique and unique globally.
The nano vaccine composed of reassembled whole cell components of cancer cells can activate the human body's specific immunity against cancer cells to a greater extent. It not only effectively eliminates primary tumors, but also has a good preventive effect on distant metastasis and can prevent cancer recurrence after surgical resection. In the mouse cancer model experiments of lung cancer, pancreatic cancer, breast cancer, melanoma, colorectal cancer, liver cancer, sarcoma and many other cancers, the efficacy is excellent, significantly better than the new antigen vaccine (polypeptide, mRNA, DC and other forms). In the mouse model test of lung cancer, pancreatic cancer, melanoma and other cancers, when the mice were treated with Ersheng vaccine alone, the tumor free recovery rate of the mice was 70-100%; When using cancer vaccines alone to prevent recurrence, the tumor free rate in mice after vaccination with cancer cells is 80% -100% for various types of cancer.
